Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q1 2025 value amounting to -$114000.0.

  • Whitehawk Therapeutics' Gains from Investment Securities rose 1739.13% to -$114000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was -$265000.0, marking a year-over-year decrease of 271.32%. This contributed to the annual value of -$518000.0 for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q1 2025, Whitehawk Therapeutics' Gains from Investment Securities is -$114000.0, which was up 1739.13% from -$151000.0 recorded in Q4 2024.
  • Whitehawk Therapeutics' Gains from Investment Securities' 5-year high stood at $4.6 million during Q2 2021, with a 5-year trough of -$159000.0 in Q2 2023.
  • Its 5-year average for Gains from Investment Securities is $700068.9, with a median of -$115000.0 in 2023.
  • In the last 5 years, Whitehawk Therapeutics' Gains from Investment Securities surged by 234385.76% in 2021 and then crashed by 48709.68% in 2023.
  • Over the past 5 years, Whitehawk Therapeutics' Gains from Investment Securities (Quarter) stood at $1.3 million in 2021, then tumbled by 97.61% to $31000.0 in 2022, then tumbled by 487.1% to -$120000.0 in 2023, then decreased by 25.83% to -$151000.0 in 2024, then rose by 24.5% to -$114000.0 in 2025.
  • Its last three reported values are -$114000.0 in Q1 2025, -$151000.0 for Q4 2024, and -$138000.0 during Q1 2024.